ReviewRSC advances2026
Hydrogel-based delivery systems for cutaneous melanoma therapy: from chemical design and crosslinking strategies to structure-activity relationships.
Review in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma, a malignant neoplasm originating from melanocytes, has exhibited a steadily rising incidence worldwide. Conventional therapeutic strategies often suffer from limited precision, resulting in significant off-target toxicity or failure to prevent disease recurrence. Hydrogels have emerged as a promising platform for localized drug delivery in cutaneous melanoma treatment, owing to their chemically designable three-dimensional networks, tunable crosslinking strategies, and excellent biocompatibility. These structural features enable controlled, on-demand release kinetics and responsiveness to the tumour microenvironment, thereby facilitating multimodal therapy such as chemotherapy, radiotherapy, phototherapy, immunotherapy, and chemodynamic therapy, with enhanced therapeutic efficacy and reduced systemic toxicity. This review systematically examines the chemical composition and crosslinking strategies underpinning hydrogel design, with an emphasis on how these structural parameters influence therapeutic outcomes. Recent advances in tumour microenvironment-responsive hydrogels are further highlighted to elucidate the structure-activity relationships that inform the rational design of next-generation drug delivery systems.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.